**Core tip:** In this minireview, we focused on the retreatment of patients with treatment failure of direct-acting antiviral agents against hepatitis C virus genotype 1b (HCV GT1b) infection. We summarized the retreatment regimens for patients with failure of peginterferon and ribavirin plus HCV NS3/4A inhibitors and for those with failure of HCV NS5A inhibitors. We also demonstrated the resistance-associated substitutions of HCV NS5B nucleos(t)ide inhibitors. Attention should be paid when selecting both the initial treatment and retreat regimens to completely eradicate HCV infection.

INTRODUCTION
============

In the interferon era, the eradication of the hepatitis C virus (HCV) has had beneficial effects, such as the regression of liver fibrosis, hepatic decompensation, and the reduction of hepatocellular carcinoma (HCC) in HCV-infected individuals\[[@B1]\]. Based on these results, in the direct-acting antiviral agents (DAAs) era, it also seems important to eradicate HCV to improve the prognosis of HCV-infected individuals.

Interferon acts on the target cells, such as hepatocytes and/or lymphocytes through the interferon receptors on their surface and induces interferon-stimulated genes (ISGs) and antiviral effects\[[@B2]\]. Almost all human cells have interferon receptors on their surfaces, and the use of interferon exhibits numerous adverse events. However, because interferon acts in a HCV-nonspecific manner, interferon can eradicate mutant viruses in most cases (Figure [1](#F1){ref-type="fig"}). The achievement of sustained virological response at week 24 after the end of treatment (SVR24) was strongly affected by single-nucleotide polymorphisms (SNPs) near the interleukin-28 B (IL28B)/interferon lambda 3-coding region in patients who were treated with peginterferon plus ribavirin, with or without DAAs\[[@B3]-[@B6]\].

![Eradication of hepatitis C virus by interferon and direct-acting antiviral agents against hepatitis C virus. A: Interferon. Interferon induces interferon-stimulated genes (ISGs) transcription after binding its receptors and antiviral proteins. ISGs eradicate hepatitis C virus (HCV) with or without resistance associated substitutions (RASs) although interleukin-28B (IL28B) genotypes have an effect on its treatment results. B: direct-acting antiviral agents (DAAs) easily eradicate HCV without RASs because DAAs work in HCV sequence-specific manner. In some cases, it is difficult for DAAs to eradicate HCV with RASs.](WJG-23-8120-g001){#F1}

HCV genome encodes at least 10 proteins: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B\[[@B7]\]. In current DAA treatment for patients infected with HCV, viral proteins targeted by HCV DAAs are HCV NS3/4A, NS5A and/or NS5B. A combination of HCV NS3/4A protease inhibitors, HCV NS5A inhibitors and/or HCV NS5B polymerase inhibitors, with or without ribavirin, are currently available for the treatment of HCV-infected patients, according to their HCV genotypes (GTs)\[[@B7]\]. Until the appearance of HCV pan-genotypic DAA regimens, most of treatments had been HCV GT-specific regimens. Representative HCV pan-genotypic drugs are shown in Table [1](#T1){ref-type="table"}.

###### 

Representative direct-acting antivirals, their targets and hepatitis C virus genotypes

  **Target regions**   **DAAs**                                    **HCV GTs**
  -------------------- ------------------------------------------- -------------
  NS3/4A               Glecaprevir                                 Pan-GTs
                       Grazoprevir                                 1, 4
                       Asunaprevir                                 1b
                       Paritaprevir                                1, 2a, 4
                       Simeprevir                                  1, 4
                       Telaprevir                                  1, 2
                       Boceprevir                                  1
  NS5A                 Pibrentasvir                                Pan-GTs
                       Velpatasvir                                 Pan-GTs
                       Elbasvir                                    Pan-GTs
                       Daclatasvir                                 Pan-GTs
                       Ledipasvir                                  1, 4, 5
                       Ombitasvir                                  1, 4
  NS5B                 Sofosbuvir \[nucleos(t)ide inhibitor\]      Pan-GTs
                       Dasabuvir \[non-nucleos(t)ide inhibitor\]   1

DAAs: Direct-acting antivirals; HCV GTs: Hepatitis C virus genotypes.

The daily oral administration of DAAs does not require injection therapy. Interferon-free treatment acts directly on HCV in a HCV RNA genome-specific manner and has fewer adverse events than interferon treatment does(Figure [1](#F1){ref-type="fig"})\[[@B8]-[@B10]\]. In interferon-era or interferon-free-era, respectively, SVR24 and SVR12 have been defined as SVR because DAA combination regimens have stronger effects. However, resistance-associated substitutions (RASs) in the HCV RNA genome at baseline reduce the efficacy of some DAA combination regimens\[[@B11]-[@B13]\]. It is well known that RASs in HCV genomes with treatment failure have significantly negative effects on the efficacy of retreatment with DAAs\[[@B14]-[@B16]\]. Ultra-deep sequencing has been used for the research purpose, but direct-sequencing method is applicable for the screening detection of RASs in daily clinical practice. When using DAA combinations, attention should be paid to the RASs and the drug-drug interactions.

Naturally occurring HCV variants depend on different geographic areas and they have some impacts on the context of current HCV therapy. Because of the high-prevalent infection of HCV GT1b in Japanese chronic hepatitis C patients, retreatment regimens of HCV GT1b is intensively discussed.

RETREATMENT OF PATIENTS INFECTED WITH HCV GT1B WITH FAILURE OF PEGINTERFERON AND RIBAVIRIN PLUS HCV NS3/4A INHIBITORS
=====================================================================================================================

Using a combination of peginterferon and ribavirin plus protease inhibitors has led to approxiately 70% SVR rates in HCV GT1b-infected patients\[[@B6],[@B17]-[@B22]\]. This combination including second generation protease inhibitors has fewer adverse events than do regimens including telaprevir or boceprevir, and it has similar SVR rates\[[@B6],[@B22]-[@B25]\].

Among HCV GT1-infected Japanese patients, 98%-99% of these patients are infected with HCV GT1b\[[@B26]\]. D168N mutations were observed in only 1.1% (1/88) of HCV GT1b NS3/4A inhibitor-treatment-naïve patients\[[@B27]\]. In Japan, resistance mutations at the HCV NS3/4A regions are not always measured before treatment with a combination of peginterferon and ribavirin plus HCV NS3/4A protease inhibitors. During and after the use of HCV NS3/4A inhibitors, treatment failure occurs in HCV GT1a patients more often than it occurs in HCV GT1b patients. We have previously summarized the resistance mutations associated with resistance to HCV NS3/4A protease inhibitors\[[@B27]\].

The American Association for the Study of Liver Diseases (AASLD)\[[@B28]-[@B31]\] has recommended a daily fixed-dose combination of sofosbuvir (400 mg)/HCV NS5A inhibitor velpatasvir (100 mg) for 12 wk, or a daily fixed-dose combination of HCV NS3/4A inhibitor glecaprevir (300 mg)/HCV NS5A inhibitor pibrentasvir (120 mg) for 12 wk, for the retreatment against HCV NS3/4A protease inhibitor with peginterferon and ribavirin-experienced, HCV GT1-patients with or without cirrhosis. They also recommended a daily fixed-dose combination of HCV NS5A inhibitor elbasvir (50 mg)/HCV NS3/4A inhibitor grazoprevir (100 mg) for 12 wk or a daily fixed-dose combination of HCV NS5A inhibitor ledipasvir (90 mg)/HCV NS5B polymerase inhibitor sofosbuvir (400 mg) for 12 wk in the retreatment for HCV GT1b patients with or without cirrhosis, respectively\[[@B28],[@B29]\].

For HCV GT1 and non-cirrhotic/cirrhotic patients who were previously treated with peginterferon and ribavirin plus HCV NS3/4A protease inhibitors, a daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) with or without ribavirin for 12 and 24 wk led to SVR rates of 96.2% (50/52)/85.7% (12/14) or 100% (51/51)/84.6% (11/13) and 97.2% (35/36)/100% (14/14) or 100% (38/38)/100% (13/13), respectively\[[@B29]\]. In the retreatment of previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors, ledipasvir plus sofosbuvir should be selected as a first-line treatment\[[@B1],[@B6],[@B28]\]. We reported that 100% SVR rates (25/25) were achieved by 12 wk of combination treatment with ledipasvir plus sofosbuvir in patients previously treated with peginterferon plus ribavirin with various HCV NS3/4A inhibitors\[[@B6]\]. It may be important to avoid drugs that target the regions targeted by initial drugs.

For HCV GT1 and cirrhotic patients who were previously treated with peginterferon and ribavirin plus DAAs, a daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for 12 wk led to 100% (48/48) SVR rates \[100% (37/37) and 100% (11/11) in GT1a and GT1b patients, respectively\]\[[@B30]\]. Among those previously treated with HCV NS3/4A protease inhibitor-based therapy without HCV NS5A inhibitor exposure who were retreated with the daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) administered as three 100 mg/40 mg fixed-dose combination pills for 12 wk, the SVR12 rates were 92% (23/25)\[[@B31]\]. These next-generation combinations of DAAs are proposed to be potential solution for the HCV GT1b-infected patients with treatment failure, mainly on a basis of targeting distinctive regions.

The use of daclatasvir plus asunaprevir for HCV GT1b was ineffective for patients with pre-existent HCV NS5A RASs or simeprevir failure, regardless of fibrosis status\[[@B32]\]. If possible, retreatment without HCV NS3/4A inhibitors should be selected for HCV GT1b-infected patients with treatment failure of peginterferon and ribavirin plus HCV NS3/4A inhibitors\[[@B6],[@B33]\].

RETREATMENT OF PATIENTS INFECTED WITH HCV GT1B WITH FAILURE OF HCV NS5A INHIBITORS
==================================================================================

HCV NS5A inhibitors, such as daclatasvir and ledipasvir, in combination with other DAAs against other regions of HCV, with or without peginterferon/ribavirin, could efficiently inhibit HCV replication, according to HCV GTs\[[@B34]\]. We have also reported the summary of resistance mutations associated with resistance to HCV NS5A inhibitors\[[@B34]\].

In Japan, daclatasvir plus HCV NS3/4A protease inhibitor asunaprevir was introduced for the treatment of chronic HCV GT1b infection in 2013\[[@B35]\]. Treatment with daclatasvir and asunaprevir after screening for HCV NS5A RASs is a relatively safe and effective treatment for HCV GT1b patients in Japan\[[@B36],[@B37]\]. However, 85.3% (29/34) of the patients with virologic failure had RASs to both daclatasvir (predominantly HCV NS5A-L31M/V-Y93H) and asunaprevir (predominantly NS3-D168 variants) detected at failure\[[@B35]\]. Japanese clinicians used the combination regimens of ledipasvir plus sofosbuvir for 12 wk in daclatasvir/asunaprevir-failure patients, resulting in only 64%-70% SVR rates\[[@B14],[@B15],[@B38]\].

The prevalence of HCV NS5A RASs was significantly higher in daclatasvir/asunaprevir-failure patients at amino acid positions 24, 28, 30, 31, 32 and 93 than it was in daclatasvir/asunaprevir-treatment naïve patients\[[@B38]\]. The presence of HCV NS5A RAS at positions 31, 32, 92, and 93 significantly attenuated the efficacy of retreatment with ledipasvir plus sofosbuvir. Of importance, HCV NS5A RASs at these positions have a negative impact on the achievement of SVR.

Recently, more effective regimens for treatment-experienced patients with HCV NS5A inhibitors have appeared\[[@B28]\], although it was recommended that treatment-experienced patients with HCV NS5A inhibitors should check their RASs or wait before further treatment\[[@B1]\]. AASLD guidelines recommend the daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/HCV NS3/4A protease inhibitor voxilaprevir (100 mg) for GT1 patients with or without cirrhosis\[[@B28]\] (See also next sections\[[@B39]\]).

HCV NS5B POLYMERASE INHIBITORS-RASs IN PATIENTS INFECTED WITH HCV GT1B
======================================================================

There are two types of HCV NS5B polymerase inhibitors: nucleos(t)ide inhibitors and non-nucleoside inhibitors. Treatment regimens including sofosbuvir, which is a nucleoside analogue, achieved higher SVR rates. RASs associated with the use of sofosbuvir are shown in Table [2](#T2){ref-type="table"}\[[@B40]-[@B44]\]. Although RASs are distributed in all domains of the HCV NS5B polymerase structure\[[@B45]\], the S282 is located at the fingers domain near the palm domain, and the C316 and V321 are both located at the palm domain\[[@B41],[@B45]\]. Of note, ribavirin associated RASs T390I and F415Y are both located in the thumb domain of HCV NS5B polymerase\[[@B42]\]. It has been reported that RASs of non-nucleoside inhibitors are the following: C316N/Y, M414I/V/T, L419M/S. R422K, M423A/I/T/B, C445F, Y448H, Y452H, I482L, A486I/T, V494A, P495A/T, V499A, P496S, G554S, S556G and D559G, which are all located at the palm and thumb domains of HCV NS5B polymerase structure\[[@B42]\].

###### 

Resistance-associated substitutions or treatment-emergent substitutions of hepatitis C virus NS5B nucleos(t)ide inhibitors

  **Domains of HCV NS5B polymerase\[[@B45]\]**   **HCV genotypes (GTs)**   **Ref**.              
  ---------------------------------------------- ------------------------- ------------ -------- --------------
  Fingers domain (AA1-188, 226-287)                                        C14R                  \[40\]
                                                                           D61G                  \[40\]
                                                                                        T77T/A   \[41\]
                                                 S96T                                            \[42\]
                                                 N142T                                  N142S    \[40,42\]
                                                 L159F                                           \[40-44\]
                                                                           E237G                 \[40\]
                                                 S282T                     S282R                 \[40-42\]
  Palm domain (AA188-226, 287-371)               M289I/L                                         \[42,44\]
                                                                           L314P                 \[40\]
                                                                                        C316R    \[41\]
                                                 L320F                     L320I/V               \[40-42\]
                                                 V321A                     V321I                 \[40,42,43\]
                                                                           T344I                 \[40\]
  Thumb domain (AA371-530)                                                 F415Y                 \[43\]
                                                                           E440G, E/G   \[42\]   
                                                 S470G                                  \[40\]   

β-hairpin, AA443-453; C-term linker, AA530-565\[[@B44]\]. HCV: Hepatitis C virus.

When treatment failure was observed in case where the first-generation HCV NS5A inhibitor plus nucleoside inhibitor such as sofosbuvir with or without ribavirin had been selected as an initial DAA treatment for HCV GT1 patients, HCV genome sequences often had HCV NS5A RASs. It has been reported in POLARIS-1 and POLARIS-4 studies that treatment with sofosbuvir/velpatasvir/voxilaprevir for 12 wk could lead to 96% (253/263) and 98% (178/182) SVR rates, respectively, in HCV GTs1-6 patients who were previously treated with DAAs\[[@B39]\]. In POLARIS-1 and POLARIS-4 studies, respectively, SVR rates of 97% (146/150) and 97% (76/78), respectively, were achieved in HCV GT1-patients, by sofosbuvir/velpatasvir/voxilaprevir for 12 wk\[[@B39]\]; 96% (97/101) and 98% (53/54) in HCV GT1a-patients; and 100% (45/45) and 96% (23/24) in HCV GT1b-patients\[[@B39]\]. Twelve weeks of treatment with a ﬁxed-dose combination of sofosbuvir/velpatasvir/voxilaprevir was effective and well tolerated among patients with GT1 infection for whom a DAA-based regimen had previously failed\[[@B39],[@B46]\].

CONCLUSION
==========

Sergi et al\[[@B47]\] reviewed that there was the association between HCV GT1b and fulminant liver failure, although HCV is a rare cause of fulminant hepatitis in Japan\[[@B48]\]. Of their two HCV RNA-positive cases with evidence of HBV infection, one case had a real coinfection showing simultaneous detection of HBV DNA in serum and liver, while the other patient was a chronic HBV carrier, seropositive for HBsAg and anti-HBc IgG but negative for anti-HBc IgM and HBV DNA in liver tissue\[[@B47]\]. It has been reported that hepatitis B reactivation during or after the treatment of DAA for chronic hepatitis C\[[@B49]\]. Similar SVR rates seem to be achieved with DAAs in HCV/HBV co-infected patients\[[@B50],[@B51]\]. However, nucleos(t)ide analogues for HBV should be added to DAA therapy for HCV when serum HBV DNA levels are elevated\[[@B1]\].

There is no doubt that new, more effective combinations of DAAs have appeared and will continue to appear in the retreatment of patients who have experienced treatment failure of DAAs. Clinicians should pay careful attention when selecting the initial treatment and retreatment regimens to completely eradicate HCV infection (Table [3](#T3){ref-type="table"}).

###### 

Retreatment regimens for patients with hepatitis C virus infection for whom the initial combination of direct-acting antivirals has failed

  **Patients**                                                                                    **APASL (2016)\[[@B1]\]**                                            **AASLD (2017)\[[@B28]\]**
  ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------
  GT1                                                                                                                                                                  
  Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure non-cirrhotic patients           Sofosbuvir/ledipasvir 12 wk                                          Sofosbuvir/ledipasvir 12 wk
  Sofosbuvir/velpatasvir 12 wk                                                                                                                                         
  Glecaprevir/pibrentasvir 12 wk                                                                                                                                       
  Peginterferon and ribavirin plus HCV NS3/4A inhibitors-failure compensated cirrhotic patients   Sofosbuvir/ledipasvir 12 wk                                          Sofosbuvir/velpatasvir 12 wk
  Glecaprevir/pibrentasvir 12 wk                                                                                                                                       
  (For GT1b) Elbasvir/grazoprevir 12 wk                                                                                                                                
  HCV NS5A inhibitors-failure non-cirrhotic patients                                              Wait                                                                 Sofosbuvir/velpatasvir/voxilaprevir 12 wk
  HCV NS5A inhibitors-failure compensated cirrhotic patients                                      RAS check                                                            Sofosbuvir/velpatasvir/voxilaprevir 12 wk
  Non-NS5A inhibitor/ sofosbuvir-failure non-cirrhotic patients                                   N/A                                                                  Glecaprevir/pibrentasvir 12 wk
  (For GT1a)                                                                                                                                                           
  Sofosbuvir/velpatasvir/voxilaprevir 12 wk                                                                                                                            
  (For GT1b) Sofosbuvir/velpatasvir 12 wk                                                                                                                              
  Non-NS5A inhibitor/ sofosbuvir-failure compensated cirrhotic patients                           N/A                                                                  Glecaprevir/pibrentasvir 12 wk
  (For GT1a)                                                                                                                                                           
  Sofosbuvir/velpatasvir/voxilaprevir 12 wk                                                                                                                            
  (For GT1b) Sofosbuvir/velpatasvir 12 wk                                                                                                                              
  GT2                                                                                                                                                                  
  Sofosbuvir/ribavirin-failure patients                                                           N/A                                                                  Sofosbuvir/velpatasvir 12 wk
                                                                                                  Glecaprevir/pibrentasvir 12 wk                                       
  GT3                                                                                                                                                                  
  DAA (including NS5A inhibitors) - failure patients                                              N/A                                                                  Sofosbuvir/velpatasvir/voxilaprevir 12 wk
                                                                                                  (For NS5A inhibitor-failure) weight-based ribavirin is recommended   
  GT4                                                                                                                                                                  
  DAA (including NS5A inhibitors) - failure patients                                              N/A                                                                  Sofosbuvir/velpatasvir/voxilaprevir 12 wk
                                                                                                                                                                       
  GT5/GT6                                                                                                                                                              
  DAA (including NS5A inhibitors) - failure patients                                              N/A                                                                  Sofosbuvir/velpatasvir/voxilaprevir 12 wk
                                                                                                                                                                       

DAAs: Direct-acting antivirals; HCV GTs: Hepatitis C virus genotypes; RAS: Resistance-associated variants; N/A: Not available.
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